Clinical trials: IBD-unclassified (IBD-U)
Crohn Disease, Pediatric Crohns Disease
PediCRaFT: Pediatric Crohn's Disease Fecal Transplant Trial
The objective of this study is to assess the feasibility of a novel colonic and oral fecal microbiota transplantation protocol for the treatment of active pediatric Crohn's disease (CD).
- Conditions
- Crohn Disease, Pediatric Crohns Disease, Inflammatory Bowel Diseases, Colitis
- Trial name
- PediCRaFT (NCT03378167)
- Testing
- MICROBIOTA
- Where
- 2 sites in Canada
- Volunteers
- 17 people
- Sponsor
- McMaster Children's Hospital
Inflammatory Bowel Disease, Ulcerative Colitis
Pediatric FEcal Microbiota Transplant for Ulcerative Colitis
The PediFETCh study is a pilot trial designed to assess the feasibility of fecal microbiota transplants for the therapy of pediatric ulcerative colitis (UC) and pediatric inflammatory bowel disease-unclassified (IBD-U).
- Trial name
- PediFETCh (NCT02487238)
- Testing
- Fecal Microbiota Enema, Normal Saline Enema
- Where
- 3 sites in Canada
- Volunteers
- 35 people
- Sponsor
- McMaster Children's Hospital
Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC)
Family Members at INcreased-risk for Developing Inflammatory Bowel Disease
First-degree relatives of people with inflammatory bowel disease ("IBD," including Crohn's disease and ulcerative colitis) have an increased risk for developing IBD themselves.
- Conditions
- Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC), IBD-unclassified (IBD-U), Indeterminate Colitis
- Trial name
- FIND-IBD (NCT06655415)
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Ulcerative Colitis (UC), IBD-unclassified (IBD-U)
Therapeutic Drug Monitoring for Biological Therapy in Pediatric Inflammatory Bowel Disease
Inflammatory Bowel Diseases (IBD), which include Crohn's disease (CD), ulcerative colitis (UC), and the unclassified form referred to as indeterminate colitis, are most commonly diagnosed during adolescence and early adulthood.
- Trial name
- TDMpIBD (NCT06954311)
- Where
- 10 sites in Austria
- Volunteers
- 120 people
- Sponsor
- Medical University Innsbruck
Inflammatory Bowel Disease (IBD), Crohn Disease (CD)
Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)
The SHIFT-IBD Study is being conducted at multiple medical centers across Canada to evaluate how well guselkumab (Tremfya) works for people with inflammatory bowel disease (IBD) who haven't responded well enough to ustekinumab.
- Conditions
- Inflammatory Bowel Disease (IBD), Crohn Disease (CD), Ulcerative Colitis (UC), IBD-unclassified (IBD-U)
- Trial name
- SHIFT-IBD (NCT07245394)
- Testing
- Guselkumab (Tremfya)
- Where
- 14 sites in Canada
- Volunteers
- 200 people
- Sponsor
- TIDHI Innovation Inc.